Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies, Reuters’ Sneha S K reports. The Biosecure Act, which was passed by the House of Representatives in September and specifically names Wuxi, must still pass the Senate before it can be signed into law by the president, Reuters notes.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Opko Health subsidiary announces EBV vaccine enters Phase I study
- Merck put volume heavy and directionally bearish
- Drug Prices Are Increasing Again in 2025, But It’s Not as Bad as It Sounds
- PFE, BMY, SNY, and Others Are Set to Raise Prices on 250 Drugs
- Merck’s sotatercept approved by MHRA to treat PAH
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
